ProSomnus to Host Investor Call and Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023
ProSomnus, Inc. (NASDAQ: OSA) announced it will release its fourth-quarter and full-year 2022 financial results on March 30, 2023, after market close. CEO Len Liptak and CFO Brian Dow will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and provide a business update.
ProSomnus specializes in precision medical devices for Obstructive Sleep Apnea (OSA). Their patented devices offer a less invasive alternative to CPAP therapy and are the most prescribed Precision Oral Appliance Therapy in the U.S., with over 200,000 devices delivered.
- ProSomnus is a pioneer in precision medical devices, indicating strong market positioning.
- Over 200,000 devices delivered, showcasing significant adoption of precision OAT devices.
- Devices are FDA-cleared and authorized by the Department of Defense, enhancing credibility.
- None.
PLEASANTON, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), the pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), will report its fourth quarter and full year 2022 financial results after market close on Thursday, March 30, 2023. ProSomnus Chief Executive Officer, Len Liptak, and Chief Financial Officer, Brian Dow, will host a conference call that day at 1:30 p.m. PT / 4:30 p.m. ET to discuss the reported results and provide a business update.
Interested parties may register for the conference call using the following link: ProSomnus Q4 Earnings Registration Link. You may access the live webcast of the conference call by using the following link: ProSomnus Q4 Earnings Call. The link will also be posted in the Investor Relations section of the ProSomnus website at News & Events.
About ProSomnus
ProSomnus (NASDAQ: OSA) precision intraoral medical devices offer effective, economical, and patient-preferred treatment for patients suffering from Obstructive Sleep Apnea (OSA). ProSomnus is the first manufacturer of mass-customized Precision Oral Appliance Therapy (OAT) devices to treat OSA, which affects over 74 million people in North America and is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes. ProSomnus’s patented, FDA-cleared devices are a less invasive and more comfortable alternative to Continuous Positive Airway Pressure (CPAP) therapy, and lead to effective and patient-preferred outcomes. A growing body of research, including studies published by the Journal of Clinical Sleep Medicine and Military Medicine, suggests ProSomnus’s Precision OAT devices are an effective treatment for mild to moderate OSA. Additional clinical research has shown that ProSomnus’s Precision OAT devices mitigate many of the side effects associated with alternative treatments and improve economics for payers and providers. With more than 200,000 devices delivered, ProSomnus’s devices are the most prescribed Precision OAT in the U.S. ProSomnus’s FDA-cleared devices are authorized by the Department of Defense and the U.S. Army, and are often covered by medical insurance, Medicare, and social health programs in key international markets. To learn more, visit www.ProSomnus.com.
Investor Contact
Mike Cavanaugh
ICR Westwicke
Phone: +1.617.877.9641
Email: Mike.Cavanaugh@westwicke.com
Media Contact
Elizabeth Coleman
ICR Westwicke
Phone: +1.203.682.4783
Email: Elizabeth.Coleman@westwicke.com
FAQ
When will ProSomnus report its Q4 and full year 2022 financial results?
What time will the ProSomnus earnings call take place?
How can I register for the ProSomnus Q4 earnings call?
What is ProSomnus's stock symbol?
What does ProSomnus specialize in?
